



February 6, 2017

Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day

LEXINGTON, MA -- (Marketwired) -- 02/06/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017.

Event: 2017 Rare Disease, Biopharma One-on-One Day

Date: Tuesday, February 7, 2017

Location: Intercontinental Barclay, 111 E 48th St, New York, NY

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Corporate Contact:

Stephen Tulipano

Aldeyra Therapeutics, Inc.

Tel: +1 781-761-4904 ext. 205

[Email Contact](#)

Investor Contact:

Chris Brinzey

Westwicke Partners

Tel: 339-970-2843

[Email Contact](#)

Media Contact:

Cammy Duong

MacDougall Biomedical Communications

781-591-3443

[Email Contact](#)

Source: Aldeyra Therapeutics

News Provided by Acquire Media